Recently, S&P Global, an internationally authoritative rating agency, has released the Sustainability Yearbook 2026 (the “Yearbook”). China Medical System (“CMS” or the “Group”) has stood out among 9,200 participating companies and successfully secured a place in the Yearbook, with a 2025 Corporate Sustainability Assessment (CSA) score of 66, surpassing 92% of global peers. This marks the second consecutive year that CMS has earned this international honor. Source: S&P Global Guided by its long-term ESG strategic objectives, CMS has deeply integrated the concept of sustainable development into its strategic decision-making and daily operations. The Group is driven by the dual engines of in-house R&D and collaborative R&D, continuously enhancing the accessibility and affordability of healthcare services and working to narrow health disparities across different regions and populations. Concurrently, we actively fulfill our corporate social responsibilities, leveraging innovative biotechnology to drive industry advancement and contribute to the sustained improvement of social well-being. Our sustainability performance has also been recognized by multiple authoritative rating agencies: MSCI ESG Rating maintained at “AA”; the Hong Kong […]
Ruxolitinib phosphate cream, as the first and only targeted drug approved in China for the treatment of vitiligo, marked a key milestone in its expansion into multiple therapeutic areas with the acceptance of its NDA for the additional indication of AD. The NDA has been included in the Priority Review List based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”which is expected to accelerate the Product’s review process for marketing approval. Ruxolitinib phosphate cream has achieved positive results in the China Phase III clinical trial for AD: At Week 8, 63.0% of subjects achieved IGA 0/1, with ≥2 grades of reduction from baseline (vs. 9.2% for placebo, P < 0.001); 78.0% of subjects achieved EASI 75 (vs. 15.4% for placebo, P < 0.001). Overall, ruxolitinib phosphate cream was safe and well-tolerated. For AD, Dermavon has developed a comprehensive “treatment […]
Lidoderm® Lidocaine Cataplasms was approved for marketing in China in 2024, and its use for postherpetic neuralgia (PHN) treatment has been supported by consensus in clinical practice guidelines both in China and abroad Leveraging the advantages of its original brand, the Product can form in-depth synergy with the Group’s existing products in terms of expert resources and marketing channels; meanwhile, the Group will actively develop diverse marketing models such as new retail, further accelerating the development of the out-of-hospital market China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 12 February 2026, the Group through subsidiaries of the Company entered into an exclusive distribution agreement (the “Agreement”) with Teikoku Pharma USA, Inc. (“TPU”, a subsidiary of Japan-based Teikoku Seiyaku Co., Ltd (“TSC”), collectively referred to as the “Cooperation Partner”) for Lidoderm® Lidocaine Cataplasms (the “Product”). In accordance with […]
CMS-D017 is a novel selective small-molecule inhibitor of complement factor B（CFB）.By targeting and inhibiting CFB, it blocks abnormal activation of the alternative complement pathway, which reduces damage to target tissues and organs caused by the membrane attack complex, and effectively slows the progression of a range of complement dysregulation-related inflammatory responses and autoimmune diseases. CMS-D017 has demonstrated excellent efficacy and safety in preclinical studies. Besides paroxysmal nocturnal hemoglobinuria(which has been approved for drug clinical trials), it is also being developed for clinical use in the treatment of complement-mediated kidney diseases, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, C3 glomerulopathy, etc.; providing a potentially better therapeutic alternative for patients. Upon approval for marketing, CMS-D017 will synergize with the marketed innovative drug Velphoro (hyperphosphatemia of Chronic Kidney Disease) and the new drug currently under NDA review, Desidustat Tablets(renal anemia), in expert networks and market resources, collectively elevating the Group’s capabilities in the field of nephrology. […]
CMS-D017 is a novel selective small-molecule inhibitor of complement factor B (CFB). By targeting and inhibiting CFB, it blocks abnormal activation of the alternative complement pathway, which reduces damage to target tissues and organs caused by the membrane attack complex, and effectively slows the progression of a range of complement dysregulation-related inflammatory responses and autoimmune diseases. CMS-D017 has demonstrated excellent efficacy and safety in preclinical studies and is being developed for clinical use in the treatment of paroxysmal nocturnal hemoglobinuria, providing a potentially better therapeutic alternative for patients. Upon approval for marketing, CMS-D017 will synergize with the marketed innovative drug Velphoro (hyperphosphatemia of Chronic Kidney Disease) and the new drug currently under NDA review, Oxemia (renal anemia), in expert networks and market resources, collectively elevating the Group’s capabilities in the field of nephrology. China Medical System Holdings Limited ( “CMS” or the “Group”) is pleased to announce that innovative drug CMS-D017 […]
Ruxolitinib phosphate cream is the first and only targeted drugapproved in China for vitiligo, which brings new hope for treatment to over 10 million vitiligo patients in China, and is of great landmark significance. The product’s two overseas Phase III clinical studies for vitiligo both met their primary endpoints, with 29.9% of patients achieving F-VASI 75 after 24 weeks of treatmentin both studies, significantly higher than the placebo groups (5% and 12.9%). Continued use up to 52 weeks showed sustained repigmentation. Additionally, real-worldstudy data in China demonstrated positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect continued to improve with prolonged treatment. This approval is poised to enrich Dermavon’sproduct portfolio – potentially synergizing with its existing marketed products and enhancing Dermavon’s market position in the field of skin health. China Medical […]
At a time of annual review and year-end conclusion, a number of major capital market events and award selections have been held intensively, and CMS has received two significant honors. On January 9, at the 2025 Hong Kong Wealth Management Summit and the 12th “Top 100 Hong Kong Listed Companies” Awards Ceremony, CMS was honored as the “Top 100 Hong Kong Listed Companies-Annual Pharmaceutical and Healthcare Innovation Pioneer”. Previously, on December 29, at the 2025 CLS 8th Investment Summit and the “Capital Market Most Value-Influential List” Awards Ceremony, CMS also received the “Most Investment Value Award”. Receiving two authoritative awards in short succession fully demonstrates the market’s high recognition of the Group’s comprehensive strength and long-term development value. As a highly credible selection event in the Hong Kong stock market, the “Top 100 Hong Kong Listed Companies” aims to identify companies listed on the Main Board with sound development […]
Recently, the 2025 Deloitte China Technology Fast Program Award Ceremony was successfully held in Wuxi, China. After a three-month selection process, Dermavon, the skin health business company of CMS, was included in the list of “Deloitte China LSHC Rising Star” by virtue of its leading innovative product layout in the skin health field, as well as its promising growth and development potential. The theme of this year’s “Technology Fast Program” selection is “Boundless Innovation, Resilient Growth”. Through the review by the Professional Committee, enterprise presentation and scoring, and other processes, the selection comprehensively evaluates enterprise valuation, technological innovation, market prospects, industry ranking, etc., and selects excellent enterprises with both innovation capabilities and growth potential, so as to encourage enterprises to break through technological boundaries and promote the continuous construction of the innovation ecosystem. Being selected into this list is a full recognition of Dermavon’s leading industry position, comprehensive and differentiated innovative product portfolio, […]
Povorcitinib is a selective oral small molecule JAK1 inhibitor undergoing clinical development in China. It has been included in the list of Breakthrough Therapeutic Drugsby CDE of China’s NMPA with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product. China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National […]
Recently, CMS has been successfully selected as a constituent stock of the Hong Kong Exchanges and Clearing Tech 100 Index (“HKEX Tech 100”). As the first Hong Kong stock index launched by HKEX, it aims to track the performance of the 100 largest-cap Hong Kong-listed companies that are highly relevant to the technology theme and eligible for the Southbound Stock Connect, covering six cutting-edge sectors including artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and intelligent driving. Its launch responds to the diversified investment demands of the capital market for the technology sector, providing investors with an efficient tool to allocate assets in leading Hong Kong-listed technology companies. This inclusion fully reflects the capital market’s recognition of CMS’s innovative development strength and investment prospects. CMS is firmly advancing its three core strategies of product innovation, commercial model reform and international expansion, and is gradually achieving the strategic transition to a “specialty-focused, innovation-excellent international […]
As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection is able to exert multiple therapeutic effects through explicitly intervening in multiple targets in the ischemic cascade with highly selective synergy. It has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. The Phase III clinical study in China met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile; the key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. If approved for marketing, Y-3 for Injection will synergize with other CNS products in expert networks and market resources, including the innovative drug VALTOCO (cluster epilepsy), Deanxit (anxiety, depression), and the improved new drug under NDA review, ZUNVEYL […]
